Siegel M, Lee SL: The epidemiology of systemic lupus erythematosus ... Takayasu V, Bonfa E, Levy NM, Kumeda C, Daud RM, Cossermelli W: Systemic lupus erythematosus in the aged: clinical and ...

Systemic lupus erythematosus is a potentially fatal autoimmune disease that is characterized by wide-spread inflammation and tissue damage that can affect any part of the body. Commonly affected ...

Now, the company has hit the brakes on its phase 2b study of the drug in lupus nephritis following four patient fatalities. An independent data monitoring committee (IDMC) recommended suspending ...

When I was diagnosed with lupus across 2014-15 (I had spent years in pain without any answers), my travels and time outdoors became limited. I was experiencing pain and fatigue that kept me from ...

Walks to end Lupus are taking place this month across the nation and on Saturday, D.C. will hold its big event to raise awareness and funds for research. The Lupus Foundation of America estimates ...

Cancel anytime. Lauren Koop Daughtrey had been dealing with the pain and fatigue of lupus even before she was officially diagnosed with the autoimmune condition. “I was just sleeping all the ...

Being diagnosed with lupus, and other chronic conditions, meant huge changes for Linda Te Au. Photo / supplied What’s It Like To Be is a fortnightly column where New Zealanders from all walks of ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis.

Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to treat patients with active lupus nephritis (LN). The phase III REGENCY ...